A Research On R&D Expenditures Accounting Policy Choice For KL Pharmaceutical

In recent years,Chinese enterprises gradually shift from manufacturing enterprises to technological innovation enterprises,and the importance of research and innovation has become increasingly prominent.China's new accounting standards promulgated in 2006 changed the R&D expenditures in development phase of the old accounting standards from "total expense" to "conditional capitalization." Conditional capitalization is conducive to the success of research and development of intangible assets cost more close to its true value,more in line with the principle of income and cost allocation,help enhance the technological innovation ability of enterprises.However,it is undeniable that the new accounting standards have also brought new problems.As the definition of the research phase and the development phase is very vague,it undoubtedly increases the difficulty and space for the financial staff to work,and the authenticity of the accounting information of enterprises will be affected,But also to the relevant regulatory authorities has brought new challenges.Therefore,this paper probes into the choice of research and development expenditure accounting policy and provides the thought for regulating the accounting policy choice behavior of Chinese enterprises,which is of great realistic significance.This paper elaborates on the topics in detail with the methods of literature analysis,empirical analysis and single case analysis.First of all,This paper makes a statement on the rules of accounting standards and the three modes of accounting treatment of r&d expenditure,and then analyzed the r&d spending motivation for the choice of accounting policy,determined the main factors affecting enterprise r&d expenditure accounting policy choice.Then take KL pharmaceutical as an example to analyze the financial data of KL pharmaceutical from 2012 to 2015,introduces the general situation of the choice of accounting policy for r&d expenditure of KL pharmaceutical,and finds the motivation behind the selection of accounting policy in KL pharmaceutical through the change of data.finally,reveals the KL pharmaceutical in the research and development expenditure in the process of accounting policy choice reflects the problems,and aims at the improvement of the enterprise r&d expenditure accounting policy Suggestions are given.The research shows that from the new accounting standards,China's enterprises,especially high-tech enterprises such as the pharmaceutical manufacturing industry tend to choose "conditional" capitalization of r&d expenditure accounting policy,but the author inthe enterprise accounting policy choice motive to explore,she found,profitability,debt contract around to smooth earnings,and so on factors can become the number one reason for business decision-making.This bad earnings management affects the reliability of accounting information quality,causing the market to make wrong feedback.On this phenomenon,can make clear from the research phase and development phase of the division standard,standardization of r&d information disclosure form and content,and so on to improve,in order to solve the problems in our current accounting standards...